Active surveillance for safety monitoring of seasonal influenza vaccines in Italy, 2015/2016 season

[1] Reed C(2012)Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine Vaccine 30 1993-1998

[2] Meltzer MI(2009)Mortality from pandemic a/H1N1 2009 influenza in England public health surveillance study BMJ 339 5213-476

[3] Finelli L(2012)Vaccines against influenza WHO position paper – November 2012 Wkly Epidemiol Rec 87 461-1904

[4] Fiore A(1999)Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study. Study for the evaluation of adverse events of influenza vaccination Vaccine 17 1898-1055

[5] Donaldson LJ(2012)Active surveillance for influenza vaccine adverse events: the integrated vaccine surveillance system Vaccine 30 1050-5508

[6] Rutter PD(2014)Vaxtracker: active on-line surveillance for adverse events following inactivated influenza vaccine in children Vaccine 32 5503-3108

[7] Ellis BM(2016)Influenza vaccine effectiveness in Italy: age, subtype-specific and vaccine type estimates 2014/15 season Vaccine 34 3102-4470

[8] Greaves FE(2014)Vaccine effectiveness against severe laboratory-confirmed influenza in children: results of two consecutive seasons in Italy Vaccine 32 4466-996

[9] Mytton OT(2014)Evaluation of safety of a/H1N1 pandemic vaccination during pregnancy: cohort study BMJ 348 g3361-3355

[10] Pebody RG(2014)Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly Clin Vaccine Immunol 21 989-418

[1] Reed C(2012)Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine Vaccine 30 1993-1998

[2] Meltzer MI(2009)Mortality from pandemic a/H1N1 2009 influenza in England public health surveillance study BMJ 339 5213-476

[3] Finelli L(2012)Vaccines against influenza WHO position paper – November 2012 Wkly Epidemiol Rec 87 461-1904

[4] Fiore A(1999)Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study. Study for the evaluation of adverse events of influenza vaccination Vaccine 17 1898-1055

[5] Donaldson LJ(2012)Active surveillance for influenza vaccine adverse events: the integrated vaccine surveillance system Vaccine 30 1050-5508

[6] Rutter PD(2014)Vaxtracker: active on-line surveillance for adverse events following inactivated influenza vaccine in children Vaccine 32 5503-3108

[7] Ellis BM(2016)Influenza vaccine effectiveness in Italy: age, subtype-specific and vaccine type estimates 2014/15 season Vaccine 34 3102-4470

[8] Greaves FE(2014)Vaccine effectiveness against severe laboratory-confirmed influenza in children: results of two consecutive seasons in Italy Vaccine 32 4466-996

[9] Mytton OT(2014)Evaluation of safety of a/H1N1 pandemic vaccination during pregnancy: cohort study BMJ 348 g3361-3355

[10] Pebody RG(2014)Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly Clin Vaccine Immunol 21 989-418